Titre : Hyperplasie lymphoïde angiofolliculaire

Hyperplasie lymphoïde angiofolliculaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hyperplasie lymphoïde angiofolliculaire : Questions médicales les plus fréquentes", "headline": "Hyperplasie lymphoïde angiofolliculaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hyperplasie lymphoïde angiofolliculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-26", "dateModified": "2025-04-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hyperplasie lymphoïde angiofolliculaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndromes lymphoprolifératifs", "url": "https://questionsmedicales.fr/mesh/D008232", "about": { "@type": "MedicalCondition", "name": "Syndromes lymphoprolifératifs", "code": { "@type": "MedicalCode", "code": "D008232", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.683.515" } } }, "about": { "@type": "MedicalCondition", "name": "Hyperplasie lymphoïde angiofolliculaire", "alternateName": "Castleman Disease", "code": { "@type": "MedicalCode", "code": "D005871", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "David C Fajgenbaum", "url": "https://questionsmedicales.fr/author/David%20C%20Fajgenbaum", "affiliation": { "@type": "Organization", "name": "Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Philadelphia, PA, USA." } }, { "@type": "Person", "name": "Angela Dispenzieri", "url": "https://questionsmedicales.fr/author/Angela%20Dispenzieri", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Mayo Clinic, Rochester, MN; and." } }, { "@type": "Person", "name": "Kazue Takai", "url": "https://questionsmedicales.fr/author/Kazue%20Takai", "affiliation": { "@type": "Organization", "name": "Department of Hematology, Niigata City General Hospital, Niigata, Japan." } }, { "@type": "Person", "name": "Eric Oksenhendler", "url": "https://questionsmedicales.fr/author/Eric%20Oksenhendler", "affiliation": { "@type": "Organization", "name": "Département d'immunologie Clinique, Hôpital Saint-Louis, Université de Paris, Paris, France." } }, { "@type": "Person", "name": "Wei Wang", "url": "https://questionsmedicales.fr/author/Wei%20Wang", "affiliation": { "@type": "Organization", "name": "Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.", "datePublished": "2022-08-17", "url": "https://questionsmedicales.fr/article/35987353", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.neuropharm.2022.109220" } }, { "@type": "ScholarlyArticle", "name": "Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis.", "datePublished": "2023-01-30", "url": "https://questionsmedicales.fr/article/36738634", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.109788" } }, { "@type": "ScholarlyArticle", "name": "The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews.", "datePublished": "2024-05-07", "url": "https://questionsmedicales.fr/article/38715038", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12913-024-11040-w" } }, { "@type": "ScholarlyArticle", "name": "Impact of mandatory COVID-19 shelter-in-place order on controlled substance use among rural versus urban communities in the United States.", "datePublished": "2022-06-16", "url": "https://questionsmedicales.fr/article/35710976", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jrh.12688" } }, { "@type": "ScholarlyArticle", "name": "Cardiopulmonary and muscular effects of different doses of high-intensity physical training in substance use disorder patients: study protocol for a block allocated controlled endurance and strength training trial in an inpatient setting.", "datePublished": "2022-09-27", "url": "https://questionsmedicales.fr/article/36167363", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-061014" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Syndromes immunoprolifératifs", "item": "https://questionsmedicales.fr/mesh/D007160" }, { "@type": "ListItem", "position": 4, "name": "Syndromes lymphoprolifératifs", "item": "https://questionsmedicales.fr/mesh/D008232" }, { "@type": "ListItem", "position": 5, "name": "Hyperplasie lymphoïde angiofolliculaire", "item": "https://questionsmedicales.fr/mesh/D005871" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hyperplasie lymphoïde angiofolliculaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hyperplasie lymphoïde angiofolliculaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hyperplasie lymphoïde angiofolliculaire", "description": "Comment diagnostiquer la maladie de Castleman ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nQuels signes cliniques indiquent une hyperplasie lymphoïde ?\nLa maladie de Castleman est-elle toujours symptomatique ?\nQuel rôle joue l'imagerie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Controlled+Substances&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quels sont les symptômes courants de la maladie de Castleman ?\nLa fatigue est-elle un symptôme de cette maladie ?\nPeut-on avoir des sueurs nocturnes avec cette maladie ?\nLes symptômes varient-ils d'un patient à l'autre ?\nY a-t-il des symptômes spécifiques à la forme multicentrique ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Controlled+Substances&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hyperplasie lymphoïde angiofolliculaire", "description": "Peut-on prévenir la maladie de Castleman ?\nY a-t-il des facteurs de risque identifiés ?\nLes habitudes de vie influencent-elles le risque ?\nLes vaccinations peuvent-elles aider ?\nLe dépistage précoce est-il utile ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Controlled+Substances&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quels traitements sont disponibles pour la maladie de Castleman ?\nLa radiothérapie est-elle utilisée dans le traitement ?\nLes corticostéroïdes sont-ils efficaces ?\nQuel est le rôle des thérapies ciblées ?\nLa surveillance est-elle nécessaire après le traitement ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Controlled+Substances&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quelles complications peuvent survenir avec Castleman ?\nLa maladie de Castleman peut-elle entraîner des infections ?\nY a-t-il un risque de cancer associé ?\nComment gérer les complications ?\nLes complications affectent-elles le pronostic ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Controlled+Substances&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hyperplasie lymphoïde angiofolliculaire", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de Castleman ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes antécédents familiaux sont-ils un facteur ?\nLe mode de vie affecte-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D005871?mesh_terms=Controlled+Substances&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la maladie de Castleman ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, l'imagerie et la biopsie des ganglions lymphatiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins, des échographies et des IRM peuvent être utilisés pour évaluer l'étendue de la maladie." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une hyperplasie lymphoïde ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des ganglions lymphatiques enflés, de la fièvre et des sueurs nocturnes peuvent indiquer la maladie." } }, { "@type": "Question", "name": "La maladie de Castleman est-elle toujours symptomatique ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques, rendant le diagnostic plus difficile." } }, { "@type": "Question", "name": "Quel rôle joue l'imagerie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie aide à visualiser les ganglions lymphatiques et à évaluer leur taille et leur nombre." } }, { "@type": "Question", "name": "Quels sont les symptômes courants de la maladie de Castleman ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des ganglions lymphatiques enflés, de la fièvre, et des douleurs abdominales." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme de cette maladie ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fatigue est fréquente et peut résulter de l'inflammation et de l'anémie associées." } }, { "@type": "Question", "name": "Peut-on avoir des sueurs nocturnes avec cette maladie ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les sueurs nocturnes sont un symptôme courant chez les patients atteints de Castleman." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'un patient à l'autre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction du type et de la gravité de la maladie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à la forme multicentrique ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la forme multicentrique peut entraîner des symptômes systémiques plus prononcés." } }, { "@type": "Question", "name": "Peut-on prévenir la maladie de Castleman ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention connue pour la maladie de Castleman." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque identifiés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'infection par le VIH et certaines maladies auto-immunes peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des habitudes de vie saines peuvent aider à réduire le risque de maladies en général." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Bien que les vaccinations ne préviennent pas Castleman, elles protègent contre d'autres infections." } }, { "@type": "Question", "name": "Le dépistage précoce est-il utile ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage précoce n'est pas standardisé pour Castleman, mais un suivi médical régulier est conseillé." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la maladie de Castleman ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et les thérapies ciblées." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée dans le traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut être utilisée pour traiter les formes localisées de la maladie." } }, { "@type": "Question", "name": "Les corticostéroïdes sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les corticostéroïdes peuvent réduire l'inflammation et soulager certains symptômes." } }, { "@type": "Question", "name": "Quel est le rôle des thérapies ciblées ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies ciblées visent des molécules spécifiques pour inhiber la croissance tumorale." } }, { "@type": "Question", "name": "La surveillance est-elle nécessaire après le traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour détecter toute récidive ou complication." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec Castleman ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance organique, l'infection et le développement de lymphomes." } }, { "@type": "Question", "name": "La maladie de Castleman peut-elle entraîner des infections ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'immunosuppression liée à la maladie peut augmenter le risque d'infections." } }, { "@type": "Question", "name": "Y a-t-il un risque de cancer associé ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent avoir un risque accru de développer des lymphomes ou d'autres cancers." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier." } }, { "@type": "Question", "name": "Les complications affectent-elles le pronostic ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la présence de complications peut aggraver le pronostic et compliquer le traitement." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les infections virales, notamment par le VIH, et certaines maladies auto-immunes sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de Castleman ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la maladie peut survenir à tout âge, mais elle est plus fréquente chez les jeunes adultes." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que les hommes peuvent être plus susceptibles de développer la maladie." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuve solide que les antécédents familiaux augmentent le risque de Castleman." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut réduire le risque de nombreuses maladies, mais son impact sur Castleman est incertain." } } ] } ] }

Sources (10000 au total)

Concordance between controlled substance receipt and post-mortem toxicology in opioid-detected overdose deaths: A statewide analysis.

Opioid overdoses are a leading cause of preventable death in the United States. There is limited research linking decedents' receipt of controlled substances and presence of controlled substances on p... We linked data on opioid-detected deaths in Connecticut between May 3, 2016, and December 31, 2017 from the Office of the Chief Medical Examiner, Department of Consumer Protection, and Department of M... Our analysis included 1412 opioid-detected overdose deaths. 47 % received an opioid or benzodiazepine 90 days prior to death; 36 % received an opioid and 27 % received a benzodiazepine. Concordance be... Our results suggest medically supplied opioids and benzodiazepines potentially contributed to a substantial number, though minority, of opioid-detected deaths during the study period. Efforts to reduc...

The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews.

Access to anaesthesia and surgical care is a major problem for people living in Sub-Saharan Africa. In this region, ketamine is critical for the provision of anaesthesia care. However, efforts to cont... This research is a mixed-methods study, comprising of a cross-sectional survey at the hospital level in Rwanda, and key informant interviews with experts on anaesthesia care in Sub-Saharan Africa. Dat... The survey conducted in Rwanda found that availability of ketamine and propofol was comparable at around 80%, while thiopental and inhalational agents were available at only about half of the hospital... Ketamine is critical for the provision of anaesthesia care in Sub-Saharan Africa, and its scheduling would have a significantly negative impact on its availability for anaesthesia care....

Impact of mandatory COVID-19 shelter-in-place order on controlled substance use among rural versus urban communities in the United States.

Mandatory COVID-19 shelter-in-place (SIP) orders have been imposed to fight the pandemic. They may also have led to unintended consequences of increased use of controlled substances especially among r... Call counts received by the poison control centers between October 19, 2019 and July 6, 2020 due to exposure to controlled substance (methamphetamine, opioids, cocaine, benzodiazepines, and other narc... During the study period, 2,649 counties in the United States had mandatory SIP orders. The rate of calls reporting exposure to any of the aforementioned controlled substances among the rural counties ... The mandatory SIP orders may have had an unintended consequence of exacerbating the use of controlled substances at home in rural communities relative to urban communities....

Cardiopulmonary and muscular effects of different doses of high-intensity physical training in substance use disorder patients: study protocol for a block allocated controlled endurance and strength training trial in an inpatient setting.

Patients with substance use disorder (SUD) have high prevalence of lifestyle-related comorbidities. Physical exercise is known to yield substantial prophylactic impact on disease and premature mortali... This study will recruit 40 in-patients of mixed genders, aged 18-70 years. Participants will be block allocated to low-dose or high-dose training, encompassing 24 high-intensity interval and maximal s... This protocol is in accordance with the Standard Protocol Items: Recommendations for Interventional Trials statement. All participants will sign a written informed consent. The Regional Committee of M... NCT04065334....

Acute, chronic, and post-mortem toxicity: a review focused on three different classes of new psychoactive substances.

New psychoactive substances (NPS) are not controlled under the Single Convention on Narcotic Drugs of 1961 or the 1971 Convention, but they may pose a public health threat. Knowledge of the main prope... We carried out a literature review collecting information on the acute, chronic, and post-mortem toxicity of these classes of NSP. We searched info in five scientific databases considering works from ... Results have shown a general lack of studies in this field given that many NPS have not had their toxicity evaluated. We observed a significant difference in the volume of data concerning acute and ch... More in-depth information about the main threats involving NPS use are needed....

Does electronic prescribing of controlled substances deter controlled substance prescribing in emergency departments?

To examine the association between electronic prescribing of controlled substances (EPCS) and controlled substance prescription patterns in U.S. emergency departments (ED).... We conducted cross-sectional analysis at both the ED level and visit level, using the 2016-2017 National Hospital Ambulatory Medical Care Surveys.... The sample included 24,296 visits to 316 EDs, 45% of which utilized EPCS. Pain-related visits were associated with significantly higher odds of prescriptions for any controlled substances (OR = 1.52; ... While EPCS transmits prescriptions directly to pharmacies in order to reduce drug diversion problems, the results indicated no significant association between EPCS use and prescriptions for Schedule I... EPCS does not appear to deter Schedule II controlled substances prescription including opioids in an ED visit. It may facilitate any and Schedule III controlled substance prescriptions when pain was i...